Abstract
There is an enormous drive to refine therapeutic designs and delivery systems, but in this review we ask if this is always the right direction? We choose to play devil's advocate, and argue that refining drug design is not always needed, and what is actually needed is a greater understanding of the biology of the disease. Here we focus on asthma and the β2-agonist group of bronchodilators as an example of how a class of therapeutic has been developed and continues to be developmentally refined. In this review, we define viralinduced exacerbations as the greatest cause of lung attacks and the most crucial time β2-agonist therapy is needed. We explore the reasons why β2-agonist therapy fails in patients with rhinovirus-induced exacerbations, and explain why further “engineered” β2-agonist therapies are likely to continue to fail in this subset of asthmatic population. We justify our perspective by returning to the biology that underlies the cause of disease and highlight the need for “more research” into alternative therapies for this population of asthmatic patients.
Keywords: β2-agonists, desensitization, exacerbations, leukotrienes, prostaglandins, rhinovirus.
Current Drug Delivery
Title:Do We Really Need to Keep Redesigning β2-agonists for the Management of Asthma?
Volume: 12 Issue: 1
Author(s): David Van Ly and Brian G.G. Oliver
Affiliation:
Keywords: β2-agonists, desensitization, exacerbations, leukotrienes, prostaglandins, rhinovirus.
Abstract: There is an enormous drive to refine therapeutic designs and delivery systems, but in this review we ask if this is always the right direction? We choose to play devil's advocate, and argue that refining drug design is not always needed, and what is actually needed is a greater understanding of the biology of the disease. Here we focus on asthma and the β2-agonist group of bronchodilators as an example of how a class of therapeutic has been developed and continues to be developmentally refined. In this review, we define viralinduced exacerbations as the greatest cause of lung attacks and the most crucial time β2-agonist therapy is needed. We explore the reasons why β2-agonist therapy fails in patients with rhinovirus-induced exacerbations, and explain why further “engineered” β2-agonist therapies are likely to continue to fail in this subset of asthmatic population. We justify our perspective by returning to the biology that underlies the cause of disease and highlight the need for “more research” into alternative therapies for this population of asthmatic patients.
Export Options
About this article
Cite this article as:
Ly Van David and Oliver G.G. Brian, Do We Really Need to Keep Redesigning β2-agonists for the Management of Asthma?, Current Drug Delivery 2015; 12 (1) . https://dx.doi.org/10.2174/1567201811666140606112918
DOI https://dx.doi.org/10.2174/1567201811666140606112918 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Targets for Promoting Wound Healing in Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Leukotriene A4 Hydrolase as a Target for Cancer Prevention and Therapy
Current Cancer Drug Targets Treating Asthma as a Neuroelectrical Disorder
Inflammation & Allergy - Drug Targets (Discontinued) Advances in Encoding of Colloids for Combinatorial Libraries: Applications in Genomics, Proteomics and Drug Discovery
Current Pharmaceutical Biotechnology A Common Molecular Motif Characterizes Extracellular Allosteric Enhancers of GPCR Aminergic Receptors and Suggests Enhancer Mechanism of Action
Current Medicinal Chemistry Autophagy Modulators and Neuroinflammation
Current Medicinal Chemistry Evaluation of Antimicrobial and Antioxidant Activities of Latex and Extracts of <i>Euphorbia monostyla</i>
Current Bioactive Compounds Inflammasome in Dendritic Cells Immunobiology: Implications to Diseases and Therapeutic Strategies
Current Drug Targets Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry How Would Composite Traditional Chinese Medicine Protect the Brain – An Example of the Composite Formula “Pien Tze Huang”
Current Medicinal Chemistry Immunomodulatory Effect of Probiotic Bacteria
Recent Patents on Inflammation & Allergy Drug Discovery Development of Safe and Economical Synthesis of Isoxazole
Letters in Organic Chemistry The Recovery of an Elderly Woman with Asthma and Diabetes from COVID-19 Infection: A Case Report
Infectious Disorders - Drug Targets Assessment of Herb-drug Interactions Based on the Pharmacokinetic Changes of Probe Drug, Midazolam
Drug Metabolism Letters Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design Pharmacogenetics and the Pharmaceutical Industry
Current Pharmaceutical Design Immunosuppression in Sepsis
Current Pharmaceutical Design Targeted Multimodal Liposomes for Nano-delivery and Imaging: An Avenger for Drug Resistance and Cancer
Current Gene Therapy Dietary Interventions in Asthma
Current Pharmaceutical Design Cucurbitacins and the Immune System: Update in Research on Anti- inflammatory, Antioxidant, and Immunomodulatory Mechanisms
Current Medicinal Chemistry